Eli Lilly Buys AtaiBeckley to Expand Depression Pipeline
Eli Lilly’s $2.8B cash deal plus up to $1B in CVRs to buy AtaiBeckley adds FDA Breakthrough BPL‑003 for TRD, with closing eyed Q3 2026.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Cryptodaily.
Want the full article?
Continue reading on Cryptodaily →